PHASE 1 STUDY OF THE BROMODOMAIN (BRD) AND EXTRA-TERMINAL DOMAIN (BET) INHIBITOR BMS-986158 IN PEDIATRIC CANCER

Registry ID

19-040

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

DANA FARBER CANCER INSTITUTE

Start date

2022-03-15

Completion date

2026-03-27

Last update

2020-02-10

Conditions

• NEUROBLASTOMA
• LYMPHOMA
• CENTRAL NERVOUS SYSTEM MALIGNANCY
• RELAPSED OR REFRACTORY SOLID TUMORS

Related clinical trials

• A PHASE 2/3 STUDY TO CHARACTERIZE AND EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF HU 14.18K322A TREATMENT GIVEN IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH HIGH-RISK NEUROBLASTOMA
• A PHASE I STUDY OF GCAR1, A CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR PARTICIPANTS WITH SELECTED RELAPSED/REFRACTORY GPNMB-EXPRESSING SOLID TUMOURS
• A PHASE III, MULTICENTRE, OPEN-LABEL, RANDOMISED STUDY EVALUATING THE EFFICACY AND SAFETY OF R-MINI-CHOP × 2 FOLLOWED BY AZD0486 VERSUS R-MINI-CHOP × 6 IN ELDERLY OR UNFIT PARTICIPANTS WITH NEWLY DIAGNOSED LARGE B-CELL LYMPHOMA (SOUNDTRACK-D2)
• PHASE I/II STUDY OF SILMITASERTIB (CX-4945) IN COMBINATION WITH CHEMOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH RELAPSED REFRACTORY SOLID TUMORS
• A PHASE 1 / 2, OPEN-LABEL STUDY OF REC-1245 IN PARTICIPANTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC CANCER
• A PHASE 3 STUDY OF DINUTUXIMAB ADDED TO INTENSIVE MULTIMODAL THERAPY FOR CHILDREN WITH NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA

View on source registry